Martinsried/Munich, 24 September, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at the Baader Investment Conference (BIC) in Munich held from 23 to 25 September.
Peter Llewellyn-Davies, Chief Financial Officer, will present at 2.15 pm (CEST) on 25 September. The presentation will be available for download on our website www.medigene.com/media-investors/reports-presentations.
Hosted by the Baader Bank Group, over 120 German and Austrian companies will present to numerous local and international institutional investors during the capital market conference, providing a comprehensive overview of their respective development. More information: www.baaderinvestmentconference.de/en/
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe